MRNA Moderna Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: MRNA

Price (delayed)

$63.65

Market cap

$25.41B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$7.99

Enterprise value

$24.92B

?
Relative Growth: Rel. Growth: 13
Relative Strength: Rel. Strength: 94
Relative Valuation: Rel. Valuation: 9
Relative Profitability: Rel. Profitability: 13

Moderna is a pioneer and leader in the field of mRNA medicine. Through the advancement of its technology platform, Moderna is reimagining how medicines are made to transform how we ...

Highlights
MRNA's gross profit has plunged by 68% YoY but it is up by 6% from the previous quarter
The gross margin has plunged by 55% YoY but it has grown by 6% from the previous quarter
The debt has surged by 77% year-on-year
The quick ratio has contracted by 38% YoY and by 8% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.modernatx.com
Peers: MRK NVS JNJ ARWR

Key stats

What are the main financial stats of MRNA

MRNA stock price

How has the Moderna stock price performed over time
Intraday
-0.03%
1 week
18.18%
1 month
-5.01%
1 year
136.71%
YTD
115.84%
QTD
-9.11%

Financial performance

How have Moderna's revenue and profit performed over time
Revenue
$2.23B
Gross profit
$521M
Operating income
-$3.32B
Net income
-$3.15B
Gross margin
23.4%
Net margin
-141.4%
MRNA's gross profit has plunged by 68% YoY but it is up by 6% from the previous quarter
The gross margin has plunged by 55% YoY but it has grown by 6% from the previous quarter
The net margin has declined by 50% year-on-year
Moderna's operating margin has decreased by 40% YoY but it has increased by 2.8% QoQ

Price vs fundamentals

How does MRNA's price correlate with its fundamentals

Growth

What is Moderna's growth rate over time

Valuation

What is Moderna stock price valuation
MRNA P/E details
P/E
N/A
P/B
3.74
P/S
11.37
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
11.19
The company's EPS fell by 6% YoY
MRNA's P/B is 63% above its last 4 quarters average of 2.3 and 7% above its 5-year quarterly average of 3.5
The equity is down by 28% YoY and by 9% QoQ
The stock's P/S is 99% above its 5-year quarterly average of 5.7 and 42% above its last 4 quarters average of 8.0
MRNA's revenue is down by 28% year-on-year

Efficiency

How efficient is Moderna business performance
The company's return on sales fell by 45% YoY
MRNA's return on equity is down by 43% year-on-year and by 7% since the previous quarter
The ROIC has contracted by 30% YoY and by 3.9% from the previous quarter
Moderna's ROA has decreased by 27% YoY

Dividends

What is MRNA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for MRNA.

Financial health

How did Moderna financials performed over time
Moderna's total assets is 161% more than its total liabilities
Moderna's total liabilities has surged by 61% YoY and by 2.9% QoQ
The current ratio has declined by 42% year-on-year and by 5% since the previous quarter
The debt is 82% smaller than the equity
The company's debt to equity has surged by 157% YoY and by 6% QoQ
The debt has surged by 77% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.